committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer. Our Mission The mission of the Alliance for Clinical Trials in Oncology is to reduce the i
Safety and tolerability of idelalisib, lenalidomide, and ritux- imab in relapsed and refractory lymphoma: the alliance for clinical trials in oncology A051201 and A051202 phase 1 trials. Lancet Hae- matol 2017;4:e176-e82.Smith SM, Pitcher BN, Jung SH, et al. Safety and tolerability of ...
Longer follow-up was necessary because the majority of the patients had estrogen receptor–positive tumors that may recur later in the disease course (the ACOSOG is now part of the Alliance for Clinical Trials in Oncology). Objective To determine whether the 10-year overall survival of patients ...
The study then continued as traditional randomized trial with a primary OS endpoint. CALGB is now part of the Alliance for Clinical Trials in Oncology. Access through your organization Check access to the full text by signing in through your organization. Access through your organization Section...
CALGB is now part of the Alliance for Clinical Trials in Oncology. Patients were randomized within 8 weeks of cancer resection. A lifestyle survey was administered in the clinic midway through, and 6 months after, chemotherapy; 1095 (87%) patients completed survey 1, and 981 (78%) patients...
“Over the past three years, the clinical trials industry has seen unprecedented change and demand, with upward trends for the number of new trials, but limited site capacity often causes delays for complex trials,” said Clare Wallis, President, Oncology Business Unit,...
thinking about our business. It is a partnership I am truly grateful for. GLSA has pivoted with us when we've moved from oncology into COVID-19 and helped advise us on critical moves with strategic clients in the space. They are truly partners with us in helping drive value for our ...
ONCare Alliance strives to support member practices by creating a business model to improve revenue, resources, and technologies reinforced by the unique shared data engine. Our mission is to sustain and enhance the independent practice of oncology by pr
” saidChristopher Flowers, M.D., division head of Cancer Medicine at MD Anderson. “We aim to explore numerous applications for MRD testing, including monitoring patients for relapse after treatment, identifying high-risk pat...
in Genentech’s oncology trials, working collaboratively to share key learnings and explore innovative ways of increasing clinical trial access for every patient who might benefit. The Alliance also plans to expand to more research centers and additional disease areas in the near future, with the ...